Table 2

The course of irHepatitis

MeasurementsResults
Days from irHepatitis diagnosis until
 Peak ALT, median (range)22 (2–94)
 Start of infliximab, median (range)17 (7–78)
 PDN ≤20 mg/day, median (range)72 (37–139)
 Baseline ALT and AST, median (range)94 (31–271)
Days from infliximab infusion until
 ALT and AST resolution to G1, median (range)26 (12–49)
 PDN ≤20 mg/day, median (range)61 (24–100)
Days to resolution to G1 from
 Diagnosis of irHepatitis, median (range)44 (22–112)
 Peak ALT, median (range)21 (10–47)
 Start of infliximab, median (range)26 (12–49)
Median follow-up after infliximab infusion, days (range)487 (64–1208)
Normal ALT and AST values at last follow-up, patients9
Received doses of infliximab (% of patients)
 16 (60)
 23 (30)
 31 (10)
  • The only patient who did not have normal values at last follow-up has succumbed to disease progression before resolution of irHepatitis.

  • ALT, alanine aminotransferase; AST, aspartate aminotransferase; G, grade; irHepatitis, immune-related hepatitis; PDN, prednisone; Peak, the highest value of ALT since first diagnosis of irHepatitis.